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Abstract
Lowe syndrome (the oculocerebrorenal syndrome of Lowe, OCRL) is a multisystem disorder
characterised by anomalies affecting the eye, the nervous system and the kidney. It is a uncommon,
panethnic, X-linked disease, with estimated prevalence in the general population of approximately
1 in 500,000. Bilateral cataract and severe hypotonia are present at birth. In the subsequent weeks
or months, a proximal renal tubulopathy (Fanconi-type) becomes evident and the ocular picture
may be complicated by glaucoma and cheloids. Psychomotor retardation is evident in childhood,
while behavioural problems prevail and renal complications arise in adolescence. The mutation of
the gene OCRL1 localized at Xq26.1, coding for the enzyme phosphatidylinositol (4,5) bisphosphate
5 phosphatase, PtdIns (4,5)P2, in the trans-Golgi network is responsible for the disease. Both
enzymatic and molecular testing are available for confirmation of the diagnosis and for prenatal
detection of the disease. The treatment includes: cataract extraction, glaucoma control, physical
and speech therapy, use of drugs to address behavioural problems, and correction of the tubular
acidosis and the bone disease with the use of bicarbonate, phosphate, potassium and water. Life
span rarely exceeds 40 years.
Disease name
Lowe and colleagues in 1952 described a unique syn-
drome with organic aciduria, decreased renal ammonia
production, hydrophthalmos and mental retardation [1].
In 1954, a renal Fanconi syndrome was recognised as
being associated with the syndrome [2] and in 1965, a








Lowe's syndrome is a very rare disease, with estimated
prevalence in the general population of approximately 1
in 500,000. According to the Lowe's Syndrome Associa-
tion (LSA) in USA, the estimated prevalence is between 1
and 10 affected males in 1,000,000 inhabitants, with 190
living in the year 2000 (0.67 × million inhabitants). The
Italian Association of Lowe's Syndrome (AISLO) esti-
mated that there were 34 Lowe's syndrome patients (33
boys and one girl) living in Italy in the year 2005 (0.63 ×
million inhabitants). Lowe's Associations operate in sev-
eral countries (USA, UK, France, Italy).
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Diagnostic criteria
Eye, central nervous system and kidney involvement are
required for the diagnosis of Lowe's syndrome. Congeni-
tal bilateral cataract is present at the birth in all patients.
Renal Fanconi syndrome may present in the first months
of life and differ in severity between individuals. It may
sometimes be asymptomatic or have an unusual clinical
presentation. Involvement of the central nervous system is
characterised by hypotonia and neonatal areflexia. Motor
and mental developmental delays are present in infancy
and stereotypic behaviour, such as temper tantrums and
aggressiveness, is frequent during adolescence. Facial dys-
morphisms are often present and consist in frontal boss-
ing, deep-set eyes, chubby cheeks and fair complexion [4].
Differential diagnosis
At birth, ocular involvement with bilateral cataract and
hypotonia may be found in congenital infections (i.e.
rubella), peroxisomal disorders, mitochondriopathies or
myotonic congenital dystrophies or congenital myopa-
thies (i.e.  Muscle-Eye-Brain disease, MEB). The appear-
ance of renal involvement excludes these alternative
diagnoses within the first months of life.
Clinical description
Signs and symptoms affecting the eye, central nervous sys-
tem and the kidneys are characteristic of the syndrome.
Eye
Dense cataract is present at birth in all patients. It devel-
ops in utero and is caused by altered migration of the crys-
talline embryonic epithelium [5]. Glaucoma (present in
50% of patients) with or without buphthalmos, is
detected within the first year of life and sometimes even
later. Sight sharpness is compromised by aphakia and,
according to some authors, together with retinal dysfunc-
tion is responsible for nystagmus. Corneal and conjuncti-
val cheloids (present in 25% of patients) further
compromise the sight.
Nervous system
A serious or very severe hypotonia is present at birth, often
with absence of the deep tendon reflex. These manifesta-
tions may compromise suction and cause serious respira-
tory problems in the first period of life. Motor
development is retarded and the autonomous gait
becomes apparent generally after the third year. About
10% of patients show slight mental retardation. Mental
retardation is moderate or severe, with an Intelligence
Quotient (IQ) of 50 or less. Numerous patients (87%)
show evidence of conduct disturbance with auto- and het-
eroaggressiveness, irritability, outbursts of anger and non-
finalised behaviour. Obsessivecompulsive behaviour is
typical [6]. Approximately 50% of the patients over 18
years old have seizures and up to 9% of the patients
present febrile convulsions [7,8]. Cranial magnetic reso-
nance imaging (MRI) may show a light ventriculomegaly
and multiple periventricular cystic lesions in a bystander
of the patients. They appear to stabilise with time and
their clinical meaning has not yet been established [7,9].
Electromyogram (EMG) and motor and sensitive velocity
are normal. No significant nerve and muscle pathologies
are present and they are not useful for diagnosis. Habitual
elevations in the levels of plasma creatine kinase (CPK)
and transaminases are also found.
Kidney
Renal disease is primarily characterised by renal Fanconi
syndrome. The severity of the renal disease can vary signif-
icantly between patients and tends to worsen with age. At
birth, many children are asymptomatic. The first symp-
toms generally develop during the first months of life and
are generally related to renal bicarbonate, salt and water
wasting, causing failure to thrive. Later, generally during
the second decade of life, a significant number of patients
develop chronic renal failure, which may lead to end-stage
renal failure and requirement for dialysis. A minority of
patients have been successfully treated with renal trans-
plantation.
Symptoms related to the renal Fanconi syndrome include:
• low molecular weight proteinuria, which appears to be
present in all patients and may be helpful for perinatal
diagnosis;
• proximal renal tubular acidosis;
• renal phosphate wasting, leading to the development of
renal rickets, osteomalacia and pathological fractures;
• hypercalciuria, leading to nephrocalcinosis and nephro-
lithiasis as a result of the Fanconi syndrome and of vita-
min D therapy;
• aminoaciduria;
• hypokaliemia, mostly related to secondary hyperaldos-
teronism [10].
Aetiology
The disease is caused by a reduction of phosphatidylinosi-
tol (4,5) bisphosphate 5 phosphatase, PtdIns (4,5)P2,
activity below 10% in fibroblasts. Accumulation of phos-
phatidylinositol (4,5) bisphosphate (PiP2), the main sub-
strate for this enzyme, in the Lowe cells and mutual
disequilibrium of the phosphoinositides (that play a cen-
tral role in cytoskeleton remodelling and in membrane
traffic) cause the clinical picture at the birth and possiblyOrphanet Journal of Rare Diseases 2006, 1:16 http://www.OJRD.com/content/1/1/16
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the late complications. The following abnormalities have
been reported in Lowe syndrome patients:
• altered cell signalling in the pathways that regulate
endocytosis [11];
• defective actin cytoskeleton polymerisation, a process
that is essential in the formation, maintenance and proper
function of tight junctions and adherens junctions. These
junctions have been demonstrated to be critical in renal
proximal tubule function and in the differentiation of the
lens [12];
• protein trafficking abnormalities.
While the genetic and enzymatic defects of Lowe syn-
drome have been thoroughly investigated, the mecha-
nisms that lead to the severe clinical manifestations are
still undefined (for review see [13]).
Genetics
Lowe syndrome is transmitted by a X-linked mode of
inheritance [3]. Two females who presented with the typ-
ical clinical picture associated with a balanced X-auto-
some translocation involving the Xq26 region [14,15],
favoured the identification of the locus [16], and the gene
was subsequently cloned by Nussbaum [17]. The causa-
tive gene OCRL1  contains 24 exons and encodes the
OCRL1 protein, an inositol polyphosphate 5 phos-
phathase (belonging to the type II 5-phosphatase family),
which localises to the trans-Golgi network [18]. To date,
several mutations have been described: truncation muta-
tions (nonsense, splicesite, frame-shift), missense muta-
tions occurring in or outside the catalytic domain of
OCRL1 and large deletions [19,20]. Somatic (i.e. muta-
tions occurring in only some cell lines during foetal devel-
opment) and germline mutations (i.e.  mutations
occurring in oocytes) have been identified in 4.5% of the
patients [21] and should be considered in genetic counsel-
ling. As the disease is a recessive X-linked disorder, only
males are usually affected but rare females with X-auto-
some translocations have been described. Recently, a
female with a single 8 base-pair mutation was identified,
with a normal karyotype and unfavourable lyonisation
(Melis and Addis 2005, personal communication).
In patients with Dent's disease, a rare X-linked renal prox-
imal tubulopathy without metabolic acidosis and neither
ocular nor brain involvement, OCRL1  mutations (but
lacked mutations in CLCN5 gene) were detected recently
[22].
Genetic counselling
De novo mutations are reported in 30% of affected males.
Germline and somatic mosaicism has been identified in
4.5% of the patients. Lowe syndrome is a X-linked disease
and the fathers are not carriers [21].
Mothers may be carriers with 25% possibility of having an
affected boy, 25% possibility of having a carrier daughter,
25% possibility of having a unaffected boy, 25% possibil-
ity of having a non-carrier girl.
Mother may be a "non carrier" if the son presents a new
mutation. In this case, chance of having another affected
child is equal to that of the general population.
Mothers with a "germline mosaicism" can not be identi-
fied by slit-lamp, enzymatic and molecular testing.
All mothers of boys affected by Lowe's syndrome should
undergo prenatal testing for possible germline mosaicism.
Carrier detection
Female carriers of Lowe syndrome may be detected in
94% of cases by slit-lamp examination because of the
presence of significantly punctuate white to grey opacities,
distributed in a radial fashion in all layers of the lenticular
cortex [23,24]. Using flanking linked markers [25], DNA
analysis can reveal the same molecular defect (in a heter-
ozygous state) as that previously identified in the patient.
Since one third of the cases are due to new mutations, and
germline mosaicism has been described, not all mothers
of affected children show the mutation. Nevertheless, pre-
natal diagnosis should be offered to all affected families.
Antenatal diagnosis
Enzymatic activity in cultured chorionic villi (at 9–11
weeks) or in cultured amniotic fluid cells (at 15–20
weeks) testing is available and should be performed if
direct molecular testing is not possible, or when a germ-
line mosaicism is suspected or when the pathogenic role
of a detected mutation is questionable (i.e.  missense
mutation).
Genetic anomalies should be documented first in the
proband. Direct molecular analysis can be performed on
DNA extracted either from a chorionic villi sample or
from cultured amniocytes. Screening for the OCRL1 gene
mutation previously detected in the affected boy should




Cataract should be removed early in order to avoid ambly-
opia. The early use of eye glasses or contact lenses
improves visual function and consequently psycho-social
skills. The ocular tone has to be tested frequently in order
to diagnose glaucoma early and to treat it either with anti-Orphanet Journal of Rare Diseases 2006, 1:16 http://www.OJRD.com/content/1/1/16
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glaucoma medication, or gonial or trabeculotomy sur-
gery. Conjunctival or corneal cheloids are difficult to treat.
Surgical lens implantation is not recommended; specta-
cles are to be preferred to contact lenses.
Nervous system
Early targeted rehabilitation therapy is necessary to treat
hypotonia and its complications. Tube feeding is not nec-
essary in the early stages of the disease. An adequate psy-
chological, pedagogical and occupational programme
favours learning capacity and prevents frequent and seri-
ous behavioural crises during adolescence.
Areflexia is a peculiar state, which does not require treat-
ment. Seizures require treatment with drugs specific for
the symptoms. The behavioural problems occurring dur-
ing adolescence and the obsessive-compulsive disorder
require specific competence on the part of the health staff.
Drugs such as neuroleptics, stimulants, benzodiazepines,
anti-depressives (tricyclic antidepressants and serotonin
reuptake inhibitors) although adequately prescribed, are
only partially efficacious. More promising results appear
to be found with clomipramine, paroxetine and risperi-
done.
Kidney
Renal tubular acidosis must be recognised and treated
promptly with alkali supplements. These include citrates
(sodium and/or potassium citrate) and sodium bicarbo-
nate in variable doses and combinations, to maintain
serum bicarbonate levels at around 20 mEq/l (doses may
vary between 1–8 mEqKg/day, which should be divided
into at least three separate doses).
Potassium citrate is particularly useful as it also helps to
prevent nephrocalcinosis and tends to reduce renal cal-
cium excretion.
If polyuria is present, patients should receive supplemen-
tary fluid. Sodium intake should be adjusted according to
the extent of renal salt loss.
In infants and very young children, oral supplements
should be promptly adjusted in case of diarrhoea. Intrave-
nous infusions may be needed.
Rickets should be treated with oral phosphate supple-
ments and vitamin D. Excessive amounts of vitamin D
should be avoided as they may increase renal calcium
excretion. Treatment should be targeted towards main-
taining serum calcium and parathormone (PTH) levels
within normal range and serum phosphate levels above
2–2.5 mg/dl.
Currently, there is no evidence that increasing the dietary
protein content above normal recommendations is of
benefit for these patients. Similarly, there is no evidence
that Lcarnitine produces any improvement.
Muscle and skeletal anomalies
Preventive treatments for the most common musculoskel-
etal complications are required to maintain articular
mobility in order to avoid contractures. Osteopaenia and
pathological fractures should be prevented by correct
treatment of rickets. Standardised therapies (including the
use of a corset and, if necessary, surgery) are required to
prevent scoliosis.
Other clinical signs
Cryptorchidism may improve with hormonal treatment
and surgery is rarely required. Use of recombinant human
growth hormone should be limited to patients with
demonstrable growth hormone deficiency.
Prognosis and quality of life
The longest reported survival is that of a 54 year-old
patient. In the very first years of life, death may occur as a
consequence of the renal disease or hypotonia, or
increased susceptibility to infectious disease (respiratory
or gastroenteric complications). The most frequent causes
of death are: respiratory illness, epileptic seizures and sud-
den death, often while sleeping. Death usually occurs
between the end of the second decade and the beginning
of the fourth decade of life. The most remote cause of
death is the renal tubulopathy, progressively evolving into
renal insufficiency.
The quality of life depends on the extent of the mental and
renal manifestations. Some patients may enjoy a discrete
social life and assisted working activity.
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